134 related articles for article (PubMed ID: 28700545)
1. FDA deems in vitro data on mutations sufficient to expand cystic fibrosis drug label.
Ratner M
Nat Biotechnol; 2017 Jul; 35(7):606. PubMed ID: 28700545
[No Abstract] [Full Text] [Related]
2. Personalized medicine. New cystic fibrosis drug offers hope, at a price.
Kaiser J
Science; 2012 Feb; 335(6069):645. PubMed ID: 22323790
[No Abstract] [Full Text] [Related]
3. Can Cystic Fibrosis Patients Finally Catch a Breath With Lumacaftor/Ivacaftor?
Schneider EK; Reyes-Ortega F; Li J; Velkov T
Clin Pharmacol Ther; 2017 Jan; 101(1):130-141. PubMed ID: 27804127
[TBL] [Abstract][Full Text] [Related]
4. Ivacaftor, vismodegib, and ingenol mebutate.
Hussar DA; Eckel SP
J Am Pharm Assoc (2003); 2012; 52(3):418-22. PubMed ID: 22618984
[No Abstract] [Full Text] [Related]
5. Lumacaftor-ivacaftor (Orkambi) for cystic fibrosis: behind the 'breakthrough'.
Mayer M
Evid Based Med; 2016 Jun; 21(3):83-6. PubMed ID: 26718821
[No Abstract] [Full Text] [Related]
6. False dawn for cystic fibrosis disease modifiers?
Holmes D
Nat Rev Drug Discov; 2014 Oct; 13(10):713-4. PubMed ID: 25270946
[No Abstract] [Full Text] [Related]
7. Cystic fibrosis drug Vertex's latest triumph.
Ledford H
Nat Biotechnol; 2012 Mar; 30(3):201-2. PubMed ID: 22398597
[No Abstract] [Full Text] [Related]
8. Excitement mounts for first disease-modifying cystic fibrosis drugs.
Opar A
Nat Rev Drug Discov; 2011 Jul; 10(7):479-80. PubMed ID: 21720393
[No Abstract] [Full Text] [Related]
9. FDA OKs first in vitro route to expanded approval.
Kingwell K
Nat Rev Drug Discov; 2017 Sep; 16(9):591-592. PubMed ID: 28860581
[No Abstract] [Full Text] [Related]
10. Rate of Uptake of Ivacaftor Use after U.S. Food and Drug Administration Approval among Patients Enrolled in the U.S. Cystic Fibrosis Foundation Patient Registry.
Sawicki GS; Dasenbrook E; Fink AK; Schechter MS
Ann Am Thorac Soc; 2015 Aug; 12(8):1146-52. PubMed ID: 26073026
[TBL] [Abstract][Full Text] [Related]
11. First cystic fibrosis drug advances towards approval.
Sheridan C
Nat Biotechnol; 2011 Jun; 29(6):465-6. PubMed ID: 21654649
[No Abstract] [Full Text] [Related]
12. Targeting a cystic fibrosis mutation opens door for personalized treatment.
Morrow T
Manag Care; 2012 Apr; 21(4):53-4. PubMed ID: 22590787
[No Abstract] [Full Text] [Related]
13. Straight talk with... Robert Beall. Interviewed by Elie Dolgin.
Beall R
Nat Med; 2012 Mar; 18(3):335. PubMed ID: 22395687
[No Abstract] [Full Text] [Related]
14. Ivacaftor (Kalydeco) for cystic fibrosis.
Med Lett Drugs Ther; 2012 Apr; 54(1388):29-30. PubMed ID: 22499233
[No Abstract] [Full Text] [Related]
15. Therapy for cystic fibrosis--the end of the beginning?
Davis PB
N Engl J Med; 2011 Nov; 365(18):1734-5. PubMed ID: 22047565
[No Abstract] [Full Text] [Related]
16. Paying twice: questions over high cost of cystic fibrosis drug developed with charitable funding.
Cohen D; Raftery J
BMJ; 2014 Feb; 348():g1445. PubMed ID: 24523379
[No Abstract] [Full Text] [Related]
17. Targeting the basic defect in cystic fibrosis.
Welsh MJ
N Engl J Med; 2010 Nov; 363(21):2056-7. PubMed ID: 21083391
[No Abstract] [Full Text] [Related]
18. Radical new treatments for cystic fibrosis.
Arch Dis Child; 2015 Aug; 100(8):727. PubMed ID: 26078470
[No Abstract] [Full Text] [Related]
19. Treating Specific Variants Causing Cystic Fibrosis.
Cutting GR
JAMA; 2017 Dec; 318(21):2130-2131. PubMed ID: 29209709
[No Abstract] [Full Text] [Related]
20. Transformative mutation specific pharmacotherapy for cystic fibrosis.
Sanders DB; Farrell PM
BMJ; 2012 Jan; 344():e79. PubMed ID: 22232540
[No Abstract] [Full Text] [Related]
[Next] [New Search]